Humana AB

As of June 30, 2026, Humana AB carries a market capitalization of 275.62M, placing it among publicly traded companies globally. Its enterprise value stands at 650.02M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Humana AB's next confirmed earnings release is scheduled for October 22, 2026.

As of June 30, 2026, Humana AB has 47.52M shares outstanding.

As of June 30, 2026, Humana AB trades at a trailing price-to-earnings ratio of 43.97. The price-to-sales ratio is 0.31, and the price-to-book ratio stands at 0.99.

As of June 30, 2026, Humana AB trades at an EV/EBITDA multiple of 8.08 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.72 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 23.92 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Humana AB trades at an EV/FCF ratio of 6.89, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 650.02M versus a market cap of 275.62M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Humana AB maintains a current ratio of 0.62, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 145.04, indicating elevated leverage, while an interest coverage ratio of 4.20 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Humana AB posted a return on equity (ROE) of 2.28, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 2.82 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 0.72, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 2.88, useful for judging operating efficiency across full business cycles. The company generates approximately 40,635.93 in revenue per employee across its workforce of 22,348.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Humana AB recorded 2.17M in income tax expense. That works out to an effective tax rate of 25.26, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 8.58M, leaving 6.41M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

These figures are as of the close on October 23, 2026.

Over the twelve months ended June 30, 2026, Humana AB generated 908.15M in revenue and converted that into 6.41M in net income, yielding earnings per share of 0.13. EBITDA reached 80.44M, while operating income came in at 27.18M.

As of June 30, 2026, Humana AB holds 30.61M in cash and equivalents against 405.01M in total debt, resulting in a net debt position of 111.32M. Total book value stands at 279.24M, with working capital of -83.78M providing operational flexibility.

Humana AB produced 79.99M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The operating margin of 2.99 and net profit margin of 0.71 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Humana AB paid dividends of 0.21 per share. The dividend payout ratio of 160.56 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 28.38, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 27.12, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Humana AB shareholders.

As of June 30, 2026, Humana AB has an Altman Z-Score of 2.96, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.